A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Conditions: Pancreatic Cancer; Pancreatic Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Metastatic; Metastatic Pancreatic Cancer; Metastatic Pancreatic Ductal Adenocarcinoma Interventions: Drug: Glipizide Sponsors: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 13, 2023 Category: Research Source Type: clinical trials
Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer
Conditions: Resectable Pancreatic Adenocarcinoma Interventions: Diagnostic Test: Injection of fluorescent developer (anti-EGFR-IR800CW) Sponsors: Zhejiang University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 13, 2023 Category: Research Source Type: clinical trials
Camrelizumab Combined With Apatinib 、Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma
Conditions: Gastroesophageal Junction Adenocarcinoma (Siewert II-III) Interventions: Drug: Camrelizumab+Apatinib+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2023 Category: Research Source Type: clinical trials
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer
Conditions: Small Cell Carcinoma of the Bladder; Small Cell Carcinoma of the Urinary Tract; Squamous Cell Carcinoma of the Bladder; Squamous Cell Carcinoma of the Urinary Tract; Primary Adenocarcinoma of the Bladder; Primary Adenocarcinoma of the Urinary Tract; Renal Medullary Carcinoma; Squamous Cell Carcinoma of the Penis Interventions: Drug: Sacituzumab govitecan; Drug: Atezolizumab Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Total Neoadjuvant Therapy for Adenocarcinoma of the OESophagus and Oesophagogastric Junction: TNT-OES-2 Trial
Conditions: Esophageal Cancer; Adenocarcinoma of the Esophagus Interventions: Drug: FLOT-CROSS or CROSS-FLOT Sponsors: Erasmus Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
Conditions: Pancreas Adenocarcinoma; Small-cell Lung Cancer; Glioblastoma, IDH-wildtype Interventions: Genetic: Long term survival multimodal analysis Sponsors: Cure 51; Gustave Roussy, Cancer Campus, Grand Paris; Centre Leon Berard; Vall d ' Hebron Institute of Oncology; Istituto Europeo di Oncologia; Charite University, Berlin, Germany Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
Conditions: Ovarian Cancer; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian Tube Cancer Interventions: Drug: Fluzoparib; Drug: Fluzoparib+Apatinib Sponsors: Guangxi Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
Conditions: Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma; HER2 Low Breast Neoplasms; HER2 Positive Breast Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms Interventions: Drug: disitamab vedotin; Drug: tucatinib Sponsors: Seagen Inc.; RemeGen Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 6, 2023 Category: Research Source Type: clinical trials
The LINFU ® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma
Conditions: Pancreatic Adenocarcinoma; Pancreatic Intraepithelial Neoplasia Sponsors: Adenocyte, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 6, 2023 Category: Research Source Type: clinical trials
A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
Conditions: Gastric Cancer/Adenocarcinoma of Esophagogastric Junction Interventions: Drug: Fruquintinib 、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 6, 2023 Category: Research Source Type: clinical trials
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Conditions: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma Interventions: Drug: Capecitabine; Drug: oxaliplatin; Drug: Disitamab Vedotin; Drug: Toripalimab Sponsors: RemeGen Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2023 Category: Research Source Type: clinical trials
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
Conditions: Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma Interventions: Other: Bio-specimen Collection: Blood; Other: Bio-specimen Collection: Pancreatic Juice; Diagnostic Test: MRI Sponsors: Mayo Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials
Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach
Conditions: Pancreatic Ductal Adenocarcinoma Interventions: Other: Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test Sponsors: Fudan University; Shanghai Weihe Medical Laboratory Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer
Conditions: Pancreatic Adenocarcinoma Interventions: Combination Product: mFOLFIRINOX plus radiotherapy Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2023 Category: Research Source Type: clinical trials
Microbiota and Metabolites Alterations in Pancreatic Head and Body/Tail Cancer Patients
Conditions: Pancreatic Ductal Adenocarcinoma (PDAC); 16S rRNA Amplicon Sequencing; Untargeted Metabolome Analysis Interventions: Other: 16S rRNA amplicon sequencing and untargeted metabolomics Sponsors: Qilu Hospital of Shandong University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 27, 2023 Category: Research Source Type: clinical trials
